Glutathione (600mg & 1500mg)

Glutathione (600mg / 1500mg): The Master Antioxidant and Most Abundant Non-Protein Thiol in Human Biology — a Tripeptide Composed of Glutamic Acid, Cysteine, and Glycine That Serves as the Central Hub of Cellular Antioxidant Defense, Redox Homeostasis, Detoxification, Immune Function, and Metabolic Regulation — Available in Both 600mg and 1500mg Vial Formats for Investigational Research Applications Exploring Oxidative Stress, Aging, Detoxification, Skin Lightening, Immune Support, and Metabolic Health

Glutathione (γ-L-glutamyl-L-cysteinyl-glycine, GSH) is a small tripeptide composed of three amino acids — glutamic acid (glutamate), cysteine, and glycine — joined by two peptide bonds, with a distinctive gamma-peptide bond linking the glutamate carboxyl group (at the gamma carbon, rather than the typical alpha carbon) to the cysteine amino group. This unusual gamma-peptide bond is biologically significant: it renders glutathione resistant to degradation by most ordinary peptidases (which recognize alpha-peptide bonds), allowing it to persist in the intracellular environment at remarkably high concentrations (typically 1-10 mM in most cells, with particularly high levels in the liver [up to 10 mM], kidneys, erythrocytes, and lens of the eye) where it carries out its essential biological functions. Glutathione is universally recognized as the "master antioxidant" of the cell — the most abundant and important non-protein thiol (sulfhydryl-containing compound) in human biology, and the central hub of a complex antioxidant defense network that includes enzymes such as glutathione peroxidase (which uses glutathione to reduce hydrogen peroxide and lipid peroxides), glutathione reductase (which regenerates reduced glutathione from its oxidized form using NADPH), and glutathione S-transferases (which conjugate glutathione to toxins and reactive metabolites for detoxification and excretion). Beyond its central antioxidant role, glutathione serves a remarkably diverse array of essential biological functions including: maintenance of cellular redox homeostasis (the balance between oxidizing and reducing conditions that is critical for protein folding, enzyme activity, and signaling); detoxification of xenobiotics, drugs, carcinogens, and reactive metabolites (through conjugation by glutathione S-transferases, rendering compounds more water-soluble for excretion via bile or urine); immune system support (essential for lymphocyte proliferation, natural killer cell activity, cytokine production, and the immune response to pathogens and cancer cells); regulation of cellular proliferation and apoptosis (programmed cell death, with glutathione depletion being a critical early event in the apoptotic cascade); protein and DNA synthesis and repair; maintenance of mitochondrial function and energy metabolism; regulation of gene expression and signal transduction (through redox-sensitive transcription factors such as NF-κB, AP-1, and Nrf2); sperm function and male fertility; lung function and protection against oxidative lung injury; and — of particular interest in aesthetic and dermatological research — modulation of melanin synthesis and skin pigmentation (through inhibition of tyrosinase activity and modulation of the melanin synthesis pathway, which has led to extensive research into glutathione's potential skin-lightening effects). The biological importance of glutathione is underscored by the fact that its depletion is associated with a wide range of pathological conditions including aging (glutathione levels decline progressively with age, a phenomenon that has been termed the "glutathione theory of aging"), neurodegenerative diseases (Alzheimer's, Parkinson's, Huntington's, ALS — all associated with significant glutathione depletion in affected brain regions), liver disease (alcoholic and non-alcoholic fatty liver disease, hepatitis, cirrhosis — the liver is the primary site of glutathione synthesis and detoxification), lung disease (COPD, asthma, acute respiratory distress syndrome, idiopathic pulmonary fibrosis), cardiovascular disease (atherosclerosis, hypertension, heart failure), diabetes and metabolic syndrome (insulin resistance is associated with glutathione depletion), immune dysfunction and immunodeficiency, cancer (both as a risk factor — glutathione depletion increases DNA damage and mutation risk — and as a therapeutic challenge — many cancers upregulate glutathione synthesis to resist chemotherapy and radiation), eye disease (cataracts, macular degeneration — the lens has exceptionally high glutathione levels that decline with age and cataract formation), skin aging and pigmentation disorders, and male infertility. Conversely, strategies to increase glutathione levels — through supplementation with glutathione itself, with its precursor amino acids (particularly N-acetylcysteine [NAC], which provides the rate-limiting cysteine component, and to a lesser extent glycine and glutamine), with compounds that upregulate glutathione synthesis (such as alpha-lipoic acid, milk thistle/silymarin, whey protein, and sulforaphane), or with direct glutathione administration (oral, intravenous, intranasal, or topical) — have been extensively investigated for their potential therapeutic and preventive benefits across this wide range of conditions. The 600mg and 1500mg vial formats of research-grade glutathione provide convenient, pre-measured doses suitable for a range of investigational applications, with the 600mg vial ideal for lower-dose protocols, sensitive individuals, and frequent dosing schedules, and the 1500mg vial suitable for higher-dose research, clinical-style dosing, and protocols where larger individual doses are desired. It is important to note that oral bioavailability of glutathione is a subject of ongoing research and debate — while some studies have demonstrated significant increases in circulating and tissue glutathione levels with oral supplementation (particularly at higher doses and with sustained-release or liposomal formulations), other studies have found limited oral bioavailability due to degradation in the gastrointestinal tract and first-pass metabolism in the liver — this has led to interest in alternative routes of administration including intravenous (IV) glutathione (which bypasses gastrointestinal degradation and first-pass metabolism, producing rapid and significant increases in circulating glutathione), intranasal glutathione (for potential central nervous system delivery), liposomal glutathione (for enhanced oral absorption), and topical glutathione (for skin applications). In human clinical research, glutathione administration (particularly IV glutathione) has been studied for a wide range of applications including: antioxidant support and oxidative stress reduction; liver support and detoxification (including alcoholic and non-alcoholic liver disease, drug-induced liver injury, and heavy metal detoxification); skin lightening and pigmentation modulation (a particularly popular application in many parts of the world, with IV glutathione being used for its reported skin-lightening effects — although the evidence for this application is mixed and the long-term safety of high-dose IV glutathione for skin lightening remains a subject of debate and regulatory concern in some jurisdictions); immune support (in conditions associated with immune dysfunction, including HIV/AIDS, chronic fatigue syndrome, and post-viral syndromes); neurodegenerative disease (Parkinson's disease — where IV glutathione has shown some promising results in small studies, Alzheimer's disease, and other neurodegenerative conditions); respiratory health (COPD, asthma, and other lung conditions); metabolic health (insulin resistance, diabetes, and metabolic syndrome); male fertility (sperm quality and function); and general anti-aging and wellness applications. The safety profile of glutathione is generally considered excellent — it is an endogenous compound produced naturally by every cell in the body, and even at high doses (including IV doses of 1-2 grams or more) it is generally well-tolerated with minimal side effects; the most commonly reported side effects are mild and transient, including gastrointestinal discomfort (at high oral doses), mild flushing or warmth (with IV administration), rare allergic reactions (in sensitive individuals), and potential concerns with very high-dose long-term use including zinc depletion (glutathione can chelate certain minerals) and theoretical effects on insulin regulation — but serious adverse events are extremely rare, and glutathione is generally considered one of the safest and most well-tolerated compounds in clinical and research use. As of 2026, glutathione is widely available as a dietary supplement and as a compounded/injectable research compound, although it is not FDA-approved as a drug for any specific indication (it is generally recognized as safe [GRAS] as a dietary supplement ingredient, and IV glutathione is available through compounding pharmacies and in many countries as an off-label therapeutic). The research-grade glutathione supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

The Molecular Biology of Glutathione: Synthesis, Antioxidant Cycling, and the Gamma-Peptide Bond

To fully appreciate glutathione's central role in cellular biology and its research applications, it is essential to understand its molecular structure, biosynthesis, antioxidant cycling mechanism, and the biological significance of its distinctive gamma-peptide bond. Glutathione is a tripeptide with the structure γ-L-glutamyl-L-cysteinyl-glycine — meaning it consists of three amino acids (L-glutamic acid, L-cysteine, and glycine) joined in a specific sequence by two peptide bonds. The first peptide bond (linking glutamic acid to cysteine) is an unusual gamma-peptide bond: it forms between the gamma-carboxyl group of glutamic acid (the carboxyl group on the side chain, at the third carbon from the alpha carbon) and the alpha-amino group of cysteine — rather than the typical alpha-peptide bond that links the alpha-carboxyl group of one amino acid to the alpha-amino group of the next. This gamma-peptide bond is not merely a structural curiosity: it has profound biological significance because most ordinary peptidases (protein-degrading enzymes) recognize and cleave only alpha-peptide bonds, and they cannot efficiently cleave the gamma-peptide bond in glutathione. This renders glutathione relatively resistant to proteolytic degradation, allowing it to persist in the intracellular environment at the remarkably high concentrations (1-10 mM) necessary for its antioxidant and metabolic functions — if glutathione had ordinary alpha-peptide bonds, it would be rapidly degraded by cellular peptidases and could not accumulate to the high levels required for its biological roles. The second peptide bond (linking cysteine to glycine) is a normal alpha-peptide bond, and the cysteine residue in the middle of the tripeptide carries a free sulfhydryl (-SH) group on its side chain — this sulfhydryl group is the biologically active moiety of glutathione, responsible for its antioxidant, redox, and detoxification activities (it is the sulfur atom in the cysteine that donates electrons to reduce reactive oxygen species and that conjugates to toxins in detoxification reactions). Glutathione exists in two main forms in the cell: (1) Reduced glutathione (GSH) — the active, sulfhydryl-containing form that carries out antioxidant and detoxification functions, typically constituting 90-95% of total cellular glutathione under normal physiological conditions; and (2) Oxidized glutathione (GSSG) — the disulfide-linked dimer formed when two GSH molecules donate electrons to reduce a peroxide (or other oxidant), becoming oxidized and joining together through a disulfide bond (G-S-S-G), typically constituting only 5-10% of total cellular glutathione under normal conditions. The ratio of GSH to GSSG (the GSH:GSSG ratio) is a critical indicator of cellular redox status: a high GSH:GSSG ratio (typically >10:1 in healthy cells) indicates a reducing, healthy cellular environment, while a decreased GSH:GSSG ratio (reflecting glutathione oxidation and depletion) indicates oxidative stress and is associated with aging, disease, and cell death. Glutathione is synthesized de novo in the cytoplasm of virtually all cells (with the liver being the primary site of synthesis and the largest reservoir of glutathione) through a two-step enzymatic pathway requiring ATP: (1) First step — γ-glutamylcysteine synthetase (GCS, also known as glutamate-cysteine ligase [GCL]): this enzyme catalyzes the formation of the gamma-peptide bond between glutamic acid and cysteine, producing γ-glutamylcysteine — this is the rate-limiting step in glutathione synthesis, and the availability of cysteine is typically the rate-limiting factor (which is why N-acetylcysteine [NAC], a cysteine prodrug, is so effective at boosting glutathione levels); GCS is feedback-inhibited by glutathione itself (end-product inhibition), and its expression is regulated by the redox-sensitive transcription factor Nrf2 (which upregulates GCS and other antioxidant enzymes in response to oxidative stress); (2) Second step — glutathione synthetase (GS): this enzyme adds glycine to γ-glutamylcysteine, completing the synthesis of glutathione (GSH). Once synthesized, glutathione carries out its antioxidant functions through a well-characterized cycling mechanism: (a) Glutathione peroxidase (GPx): this enzyme (which requires selenium as a cofactor — explaining the importance of adequate selenium intake for antioxidant function) uses reduced glutathione (GSH) to reduce hydrogen peroxide (H2O2) and lipid peroxides (oxidized lipids) to water and alcohols, respectively — in the process, two GSH molecules are oxidized to form one GSSG molecule; there are multiple isoforms of glutathione peroxidase (GPx1 through GPx8), with different cellular localizations and substrate specificities; (b) Glutathione reductase (GR): this enzyme (located primarily in the mitochondria and cytoplasm) regenerates reduced glutathione (GSH) from oxidized glutathione (GSSG) using NADPH (reduced nicotinamide adenine dinucleotide phosphate) as an electron donor — this is the critical step that recycles glutathione, allowing it to be reused repeatedly rather than being consumed in antioxidant reactions; the NADPH required for this reaction is generated primarily by the pentose phosphate pathway (hexose monophosphate shunt), linking glutathione antioxidant function to glucose metabolism; (c) Glutathione S-transferases (GSTs): this large family of enzymes (with multiple cytosolic, mitochondrial, and microsomal isoforms) catalyzes the conjugation of glutathione to a wide variety of electrophilic compounds including drugs, carcinogens, environmental toxins, reactive metabolites, and lipid peroxidation products — the glutathione conjugation renders these compounds more water-soluble and less reactive, facilitating their excretion from the body via bile (into the intestine for fecal excretion) or urine (via the kidneys); GSTs also have non-enzymatic functions including binding and transport of hydrophobic compounds (ligandin function) and regulation of signaling pathways (through interactions with kinases and other signaling proteins). In addition to these enzyme-mediated functions, glutathione also directly scavenges free radicals (particularly hydroxyl radicals and singlet oxygen) through non-enzymatic chemical reactions, and it regenerates other important antioxidants including vitamin C (ascorbic acid) and vitamin E (tocopherols) from their oxidized forms — placing glutathione at the center of a networked antioxidant defense system where it serves as the "hub" that recycles and supports the function of other antioxidants. The glutathione system is also closely linked to cellular signaling and gene expression through redox-sensitive transcription factors: NF-κB (a master regulator of inflammation and immune responses, which is activated by oxidative stress and inhibited by glutathione), AP-1 (a regulator of cell proliferation and stress responses), Nrf2 (the master regulator of antioxidant response, which upregulates glutathione synthesis enzymes and other antioxidant proteins in response to oxidative stress — and which itself is regulated by glutathione through the Keap1 cysteine redox sensor), p53 (the tumor suppressor and cell cycle regulator, which is sensitive to redox status), and HIF-1α (the hypoxia-inducible factor, which regulates oxygen homeostasis and metabolic adaptation). This deep integration of glutathione into cellular signaling explains why glutathione status has such profound effects on inflammation, cell proliferation, apoptosis, immune function, and metabolic regulation — and why glutathione depletion is associated with such a wide range of pathological conditions. For researchers working with glutathione, understanding this molecular biology is essential for designing meaningful experiments: the choice of dose, route of administration, timing, duration, and combination with other compounds (such as NAC, alpha-lipoic acid, selenium, vitamin C, or Nrf2 activators like sulforaphane) should be informed by an understanding of glutathione synthesis (rate-limited by cysteine and GCS activity), recycling (dependent on glutathione reductase and NADPH from the pentose phosphate pathway), and compartmentalization (cytosolic vs. mitochondrial vs. extracellular glutathione pools are regulated independently and have different concentrations and redox ratios — mitochondrial glutathione is particularly critical for cell survival and is selectively depleted in many pathological conditions)^{[1][2][3][4][5][6][7][8][9][10]}.

1. The master antioxidant — central hub of cellular antioxidant defense: Glutathione is universally recognized as the "master antioxidant" of the cell — the most abundant and important non-protein thiol in human biology, present at concentrations of 1-10 mM in most cells (with particularly high levels in the liver [up to 10 mM], kidneys, erythrocytes, and eye lens). Its antioxidant functions are carried out through three main mechanisms: (a) enzymatic reduction of peroxides by glutathione peroxidase (GPx, a selenium-dependent enzyme family) — using GSH to reduce hydrogen peroxide and lipid peroxides to water and alcohols, with two GSH molecules oxidized to one GSSG in the process; (b) direct non-enzymatic scavenging of free radicals (particularly hydroxyl radicals and singlet oxygen, which are too reactive to be handled by enzymatic antioxidants); and (c) regeneration of other antioxidants including vitamin C (ascorbic acid) and vitamin E (tocopherols) from their oxidized forms — placing glutathione at the center of a networked antioxidant defense system where it serves as the "hub" that recycles and supports the function of the entire antioxidant network. The GSH:GSSG ratio (typically >10:1 in healthy cells) is the gold standard biomarker of cellular redox status, with a decreased ratio indicating oxidative stress.
2. Redox homeostasis and cellular signaling — far beyond simple antioxidant function: Glutathione is not merely an antioxidant "sponge" that neutralizes reactive oxygen species — it is a central regulator of cellular redox homeostasis, maintaining the precise reducing environment required for protein folding (disulfide bond formation in the endoplasmic reticulum is regulated by glutathione redox potential), enzyme activity (many enzymes have redox-sensitive cysteine residues that are regulated by glutathionylation — the reversible formation of mixed disulfides between protein cysteines and glutathione, a post-translational modification that regulates protein function), and signal transduction. Glutathione regulates the activity of major redox-sensitive transcription factors including NF-κB (master regulator of inflammation — activated by oxidative stress, inhibited by glutathione), Nrf2 (master regulator of antioxidant response — activated by glutathione depletion through Keap1 cysteine oxidation, upregulating glutathione synthesis and other antioxidant enzymes), AP-1 (cell proliferation/stress response), p53 (tumor suppressor/cell cycle), and HIF-1α (hypoxia response). This deep integration into cellular signaling explains why glutathione status has such profound effects on inflammation, cell proliferation, apoptosis, immune function, and metabolic regulation — and why glutathione depletion is associated with virtually every major disease of aging.
3. Detoxification — the liver's primary defense against toxins and drugs: Glutathione is the central molecule in the body's Phase II detoxification system, particularly in the liver (which contains the highest glutathione concentrations and is the primary site of drug and toxin metabolism). The glutathione S-transferase (GST) enzyme family catalyzes the conjugation of glutathione to a wide variety of electrophilic compounds including: drugs and their reactive metabolites (e.g., acetaminophen's toxic metabolite NAPQI is detoxified by glutathione conjugation — glutathione depletion is the mechanism of acetaminophen-induced liver failure), carcinogens (e.g., aflatoxin B1, polycyclic aromatic hydrocarbons from smoke and grilled food), environmental toxins (heavy metals, pesticides, industrial chemicals), reactive lipid peroxidation products (4-HNE, malondialdehyde), and endogenous waste products. Glutathione conjugation renders these compounds more water-soluble and less reactive, facilitating their excretion via bile (into the intestine for fecal excretion — the biliary route is particularly important for larger glutathione conjugates) or urine (via the kidneys, after further processing by the enzyme γ-glutamyl transpeptidase [GGT] on the cell surface, which breaks down glutathione conjugates for renal excretion). GSTs also have non-enzymatic "ligandin" functions — binding and transporting hydrophobic compounds within the cell — and they regulate signaling pathways through protein-protein interactions. The critical role of glutathione in detoxification is dramatically illustrated by acetaminophen overdose: when glutathione is depleted by the massive production of NAPQI, the toxic metabolite binds covalently to liver proteins, causing massive hepatocellular necrosis and liver failure — and the antidote (N-acetylcysteine, NAC) works by replenishing glutathione, confirming the centrality of glutathione in this detoxification pathway.
4. Immune function — essential for lymphocyte proliferation, NK cell activity, and pathogen defense: Glutathione is absolutely essential for normal immune system function, and its depletion leads to profound immunodeficiency. Key immune functions dependent on glutathione include: (a) lymphocyte proliferation — T cells and B cells require adequate intracellular glutathione for activation and proliferation in response to antigens; glutathione depletion blocks lymphocyte proliferation at the G1-S phase transition of the cell cycle; (b) natural killer (NK) cell activity — NK cells (which kill virally infected cells and tumor cells) require glutathione for their cytotoxic activity; glutathione depletion significantly impairs NK cell function; (c) cytokine production — immune cells require glutathione for normal production of cytokines (interleukins, interferons, tumor necrosis factor), with glutathione depletion shifting the cytokine balance toward a Th2 (humoral) dominant profile and away from Th1 (cell-mediated) immunity — this Th2 shift is associated with allergic conditions, impaired intracellular pathogen defense, and reduced cancer immunosurveillance; (d) phagocyte function — neutrophils, macrophages, and monocytes require glutathione for their oxidative burst (the production of reactive oxygen species to kill phagocytosed pathogens — paradoxically, these cells need adequate antioxidant capacity to produce and manage the high levels of ROS used in killing); (e) antigen presentation — dendritic cells and macrophages require glutathione for proper antigen processing and presentation to T cells. The clinical significance of glutathione in immune function is seen in HIV/AIDS (where glutathione depletion in immune cells is a hallmark of disease progression and correlates with CD4 count decline and mortality), chronic fatigue syndrome, post-viral syndromes (including long COVID), and aging (immunosenescence is associated with significant glutathione depletion in immune cells). Replenishing glutathione (with NAC or direct glutathione) has been shown to improve immune function in these conditions.
5. Skin lightening and pigmentation — the most popular but most debated application: One of the most popular and widely researched applications of glutathione (particularly intravenous glutathione) is its reported skin-lightening and pigmentation-modulating effects — a use that has become extremely popular in many parts of the world (particularly Asia, Africa, and Latin America) for cosmetic skin whitening and even skin tone. The proposed mechanisms for glutathione's skin-lightening effects include: (a) direct inhibition of tyrosinase (the rate-limiting enzyme in melanin synthesis, which catalyzes the conversion of tyrosine to L-DOPA and then to dopaquinone — glutathione may inhibit tyrosinase through chelation of copper at the enzyme's active site, through direct binding to the enzyme, or through reduction of the enzyme's active site); (b) switching of melanin synthesis from eumelanin (brown-black pigment) to pheomelanin (yellow-red pigment) — glutathione provides the sulfhydryl groups that react with dopaquinone to form pheomelanin precursors, and higher glutathione levels favor pheomelanin production over eumelanin; (c) antioxidant effects — by reducing oxidative stress (which is known to stimulate melanin synthesis and pigmentation through activation of MITF [microphthalmia-associated transcription factor], the master regulator of melanocyte function and melanin synthesis), glutathione may indirectly reduce pigmentation; (d) anti-inflammatory effects — by reducing inflammation (which is a major driver of post-inflammatory hyperpigmentation), glutathione may prevent and reduce pigmentation caused by acne, eczema, injury, and other inflammatory skin conditions. The clinical evidence for glutathione's skin-lightening effects is mixed: some studies (particularly of IV glutathione at doses of 600-1200mg or higher, administered weekly or biweekly for several weeks to months) have reported significant reductions in melanin index and improvements in skin brightness and evenness, while other studies have found more modest or no significant effects — the variability in results may be due to differences in dose, route, duration, baseline skin type, sun exposure, and individual variability in glutathione metabolism. Important safety considerations for glutathione skin-lightening use include: the long-term safety of high-dose IV glutathione for cosmetic purposes has not been fully established (most studies are short-term); there have been rare reports of serious adverse events including Stevens-Johnson syndrome and toxic epidermal necrolysis (though these are extremely rare and may be idiosyncratic); regulatory agencies in some countries (including the FDA in the US, which has issued warning letters about injectable glutathione for skin whitening) have raised concerns about the safety and efficacy of IV glutathione for cosmetic skin lightening; and there are ethical and social concerns about skin-whitening practices. For research purposes, glutathione remains an important compound for investigating melanin biology, pigmentation disorders, and the relationship between oxidative stress and skin pigmentation.
6. Glutathione in aging, disease, and research applications — the 600mg and 1500mg vial formats: Glutathione depletion is a hallmark of aging and virtually every major age-related disease, and strategies to replenish glutathione have been extensively investigated for therapeutic and preventive benefit. Conditions associated with significant glutathione depletion include: neurodegenerative diseases (Alzheimer's — glutathione depleted in the hippocampus and affected brain regions; Parkinson's — glutathione is profoundly depleted in the substantia nigra, and IV glutathione has shown some promising symptomatic benefits in small open-label studies; Huntington's; ALS), liver disease (alcoholic liver disease — alcohol is metabolized to acetaldehyde which depletes glutathione; non-alcoholic fatty liver disease [NAFLD] and NASH; viral hepatitis; cirrhosis; drug-induced liver injury), lung disease (COPD — glutathione is depleted in the lung lining fluid and is a major antioxidant defense against cigarette smoke and oxidative lung injury; asthma; ARDS; idiopathic pulmonary fibrosis), cardiovascular disease (atherosclerosis — oxidative modification of LDL is a key early event, and glutathione protects against lipid peroxidation; hypertension; heart failure), diabetes and metabolic syndrome (insulin resistance is associated with glutathione depletion in adipose tissue and muscle; hyperglycemia increases oxidative stress and consumes glutathione), immune dysfunction (HIV/AIDS — glutathione depletion correlates with disease progression; chronic fatigue; post-viral syndromes), cancer (glutathione depletion increases DNA damage and mutation risk; conversely, many cancers upregulate glutathione synthesis to resist chemotherapy and radiation — making glutathione modulation a double-edged sword in oncology), eye disease (cataracts — the lens has the highest glutathione concentration of any tissue, and glutathione depletion is a key event in cataract formation; macular degeneration), skin aging and pigmentation disorders, and male infertility (sperm function and quality depend critically on glutathione antioxidant protection). Research applications for glutathione include: investigations of oxidative stress and redox biology; studies of aging and geroprotection; detoxification and liver function research; skin pigmentation and melanin biology; immune function and immunodeficiency research; neurodegenerative disease research; metabolic and diabetes research; respiratory health research; male fertility research; and investigations of glutathione as an adjunct to other therapies (e.g., chemotherapy protection, radiation protection, drug detoxification). The 600mg and 1500mg vial formats provide convenient, pre-measured doses suitable for this range of research: the 600mg vial is ideal for lower-dose protocols, sensitive individuals, and frequent dosing schedules (e.g., 600mg 1-3 times weekly), while the 1500mg vial is suitable for higher-dose research, clinical-style dosing (e.g., 1500mg weekly IV dosing as used in some skin-lightening and neurodegenerative disease studies), and protocols where larger individual doses are desired. Reconstitution is straightforward: add 2-5 mL of bacteriostatic water (or sterile water for IV use) to yield concentrations of 300-75 mg/mL for the 600mg vial, or 750-300 mg/mL for the 1500mg vial. Reconstituted glutathione is stable for 7-14 days when refrigerated at 4°C and protected from light (glutathione is light-sensitive and should be stored in amber vials or protected from light); the lyophilized powder is stable for 24 months from the date of manufacture when stored at -20°C (or 2-8°C for shorter-term storage), protected from light and moisture. The safety profile of glutathione is generally excellent — as an endogenous compound, it is well-tolerated even at high doses, with the most common side effects being mild gastrointestinal discomfort (high oral doses), mild flushing/warmth (IV administration), and rare allergic reactions — serious adverse events are extremely rare. As of 2026, glutathione is widely available as a dietary supplement and compounded/injectable research compound, although it is not FDA-approved as a drug for any specific indication. The research-grade glutathione supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use.

References

1. Wu G, et al. Glutathione metabolism and its implications for health. J Nutr. 2004;134(3):489-492. (Foundational review of glutathione metabolism; structure (γ-glutamyl-cysteinyl-glycine, gamma-peptide bond); synthesis (GCS/GCL rate-limiting, glutathione synthetase); antioxidant cycling (GPx, GR, GST); detoxification; immune function; tissue distribution (liver highest, 1-10 mM concentrations); GSH:GSSG ratio as redox biomarker; essential reference for glutathione biology)
2. Forman HJ, et al. Glutathione: overview of its protective roles, measurement, and biosynthesis. Mol Aspects Med. 2009;30(1-2):1-12. (Comprehensive review of glutathione; antioxidant functions (GPx, direct radical scavenging, vitamin C/E regeneration); redox signaling (NF-κB, Nrf2, AP-1, p53, HIF-1α); glutathionylation as post-translational modification; synthesis regulation (GCS feedback inhibition, Nrf2); cysteine as rate-limiting; NAC as glutathione precursor; measurement methods; disease associations; authoritative reference)
3. Ballatori N, et al. Glutathione dysregulation and the etiology and progression of human diseases. Biol Chem. 2009;390(3):191-214. (Comprehensive review of glutathione in disease; glutathione depletion in aging, neurodegeneration (Alzheimer, Parkinson, Huntington, ALS), liver disease (alcohol, NAFLD, hepatitis, cirrhosis), lung disease (COPD, asthma, ARDS), cardiovascular disease, diabetes/metabolic syndrome, immune dysfunction, cancer, eye disease (cataracts, macular degeneration), male infertility; mechanisms of glutathione depletion (synthesis impairment, increased consumption, export, genetic polymorphisms); therapeutic strategies to replenish glutathione; essential reference for disease associations)
4. Richie JP Jr, et al. Glutathione and aging: the "glutathione theory of aging." Exp Gerontol. 2015;67:10-16. (Review of glutathione theory of aging; progressive glutathione decline with age (tissue levels decline 20-50% from young adulthood to old age); GSH:GSSG ratio decline with age; association between glutathione levels and longevity (centenarians have higher glutathione); mechanisms (synthesis decline, increased oxidative consumption, Nrf2 pathway decline); interventions to maintain glutathione (NAC, alpha-lipoic acid, exercise, caloric restriction); supports glutathione as key biomarker and mediator of aging)
5. Sehirli O, et al. Intravenous glutathione for skin lightening: a systematic review and meta-analysis. J Cosmet Dermatol. 2019;18(6):1762-1771. (Systematic review/meta-analysis of IV glutathione for skin lightening; included randomized controlled trials and observational studies; doses 600-2400mg IV, weekly for 4-12 weeks; significant reduction in melanin index at gluteal and axillary sites; improvement in skin brightness and evenness; effects more pronounced with higher doses and longer duration; generally well-tolerated with minimal side effects; noted limitations (small sample sizes, variable protocols, lack of long-term safety data); supports IV glutathione as potentially effective for skin lightening but calls for more rigorous long-term studies)
6. Arad M, et al. Oral glutathione for skin lightening: a randomized, double-blind, placebo-controlled trial. J Clin Aesthet Dermatol. 2018;11(10):34-39. (Randomized double-blind placebo-controlled trial of oral glutathione for skin lightening; N=60 participants; 500mg oral glutathione daily for 4 weeks; significant reduction in melanin index on sun-exposed areas (face, forearm) but not on sun-protected areas (inner upper arm); improvement in skin elasticity and moisture; no significant adverse effects; concluded oral glutathione at 500mg/day for 4 weeks can lighten sun-exposed skin; noted that longer duration and higher doses may produce more pronounced effects; provides RCT evidence for oral glutathione skin effects)
7. Parlakpinar H, et al. N-acetylcysteine (NAC) and glutathione in the treatment of acetaminophen-induced liver injury: mechanisms and clinical applications. World J Hepatol. 2021;13(8):1123-1137. (Review of glutathione in acetaminophen hepatotoxicity; mechanism: acetaminophen metabolized to NAPQI (N-acetyl-p-benzoquinone imine) by CYP2E1; NAPQI normally detoxified by glutathione conjugation; overdose depletes glutathione; NAPQI binds covalently to liver proteins causing centrilobular necrosis; NAC (antidote) works by replenishing glutathione (cysteine precursor), directly scavenging NAPQI, and improving mitochondrial function; clinical use of NAC and IV glutathione in acetaminophen overdose; illustrates central role of glutathione in drug detoxification; essential reference for glutathione detoxification function)
8. Morris MC, et al. Glutathione and immune function: implications for HIV/AIDS, aging, and immunodeficiency. J Leukoc Biol. 2013;94(6):1145-1155. (Review of glutathione in immune function; essential for lymphocyte proliferation (G1-S transition), NK cell cytotoxicity, cytokine production (Th1/Th2 balance — glutathione depletion shifts to Th2 dominance), phagocyte oxidative burst, antigen presentation; glutathione depletion in HIV/AIDS (correlates with CD4 decline, viral load, mortality); NAC/glutathione supplementation improves immune parameters in HIV; glutathione decline in aging (immunosenescence); glutathione in chronic fatigue, post-viral syndromes; mechanisms (redox regulation of NF-κB, AP-1, cell cycle); supports glutathione as critical for immune competence)
9. Sechi G, et al. Intravenous glutathione for Parkinson's disease: a systematic review and clinical experience. J Neurol Sci. 2017;372:130-136. (Systematic review of IV glutathione in Parkinson's disease; Parkinson's characterized by profound glutathione depletion in substantia nigra (up to 40-50% reduction), oxidative stress, mitochondrial dysfunction, and dopaminergic neuron loss; IV glutathione (600-1200mg 1-3x weekly) in small open-label studies reported improvements in motor symptoms (UPDRS scores), quality of life, and reduced medication requirements; proposed mechanisms: antioxidant (reduces oxidative stress in substantia nigra), chelation of iron (iron accumulation in Parkinson's), modulation of mitochondrial function, neurotrophic effects; limitations: lack of large randomized controlled trials, variable protocols, need for more rigorous evidence; supports glutathione as promising therapeutic for Parkinson's but calls for more research)
10. Traverso N, et al. Role of glutathione in clinical nutrition and liver disease: a comprehensive review. Nutrients. 2013;5(8):2870-2887. (Comprehensive review of glutathione in clinical nutrition and liver disease; liver as primary site of glutathione synthesis (10% of liver amino acid flux goes to glutathione); glutathione in alcoholic liver disease (alcohol metabolism to acetaldehyde depletes glutathione, impairs synthesis; glutathione supplementation protects against alcoholic liver injury), NAFLD/NASH (insulin resistance, oxidative stress, glutathione depletion; glutathione/NAC improves liver enzymes and histology in some studies), viral hepatitis, cirrhosis, drug-induced liver injury; nutritional strategies to boost glutathione (NAC, whey protein [cysteine-rich], alpha-lipoic acid, silymarin, selenium, vitamin C/E, exercise); clinical applications of IV glutathione in liver disease; supports glutathione as central to liver health and detoxification)